i3 Genesis

i3 Genesis is an annual funding opportunity for early-stage healthcare technologies with clear potential for commercialization. Part of MSIP’s i3 Family of Funds, this opportunity aims to support and translate innovations by providing up to $50K to achieve value inflection points.

Innovators seeking to develop their technology with the potential for commercialization can submit a proposal during the Request for Proposals (RFP) period. Submitted proposals are evaluated by a review panel of experts from the MSIP Business Development team in fields including digital health, medical devices, and therapeutics. Some will be selected to pitch their proposal to the review panel during a virtual session conducted via Zoom. Proposals will be judged and scored based on project novelty, feasibility, and market risks against the budget and milestones provided. Awardees will be selected based on recorded scores and recommendations from the review panel. Funding will be disbursed to awardees once the Principal Investigator and their Administrator sign an Informed Participation Letter (IPL). More details will be provided should you be selected for i3 Genesis funding.

The RFP period for 2023 is now closed. Please check back on this page for updates.

Eligible applicants must:

Proposals involving Human Subjects or Animal Research require extra steps, such as gaining formal approval from the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC).

For more information, please reach out to Louise Lammers, PhD, Director of Business Development, Emerging Assets at louise.lammers@mssm.edu or William Chiang, PhD, Business Development Consultant, at william.chiang@mssm.edu.